Scott Worswick, MD
Dermatology · Los Angeles, CANPI 1871733329
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,200 of the $72,030 with a category attached, or 65.5%. Boehringer Ingelheim accounts for 95.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $39,808 and has fallen 91.6% since, to $3,344 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $580.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$69K
- UCB, Inc.$723
- E.r. Squibb & Sons, L.L.C.$628
- AbbVie$475
- Novartis$348
- Dermavant Sciences, Inc.$148
- plus $721 from 11 others
What the payments were for
- Consulting fees$15,65522%
- Speaking & faculty fees$47,20066%
- Travel & lodging$4,0406%
- Food & beverage$5,0627%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 61 | $68,987 |
| UCB, Inc. | 10 | $723 |
| E.r. Squibb & Sons, L.L.C. | 15 | $628 |
| AbbVie | 16 | $475 |
| Novartis | 6 | $348 |
| Dermavant Sciences, Inc. | 1 | $148 |
| Springworks Therapeutics, Inc. | 1 | $135 |
| Sanofi | 1 | $120 |
| Sanofi-aventis U.S. LLC | 2 | $112 |
| Pfizer | 1 | $81 |
| Cipher Pharmaceuticals US LLC | 1 | $69 |
| Lilly USA, LLC | 2 | $55 |
| Regeneron | 2 | $54 |
| Amgen | 2 | $32 |
| Johnson & Johnson | 1 | $31 |
| Bristol Myers Squibb | 1 | $17 |
| Smith+Nephew | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,030 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $235,418 |
| Humira(Cf) PenAdalimumab | 12 | $163,483 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $108,052 |
| OtezlaApremilast | 22 | $102,838 |
| Dupixent SyringeDupilumab | 24 | $91,977 |
| Dupixent PenDupilumab | 22 | $82,073 |
| Clobetasol Propionate | 20 | $4,609 |
| Acitretin | 11 | $3,918 |
| Timolol Maleate | 20 | $2,333 |
| Ketoconazole | 96 | $1,338 |
| Clindamycin Phosphate | 25 | $1,249 |
| Tacrolimus | 12 | $1,097 |
| Fluocinonide | 21 | $970 |
| Betamethasone Dipropionate | 18 | $869 |
| Triamcinolone Acetonide | 74 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $32 | $102,83822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.
Other dermatology in Los Angeles
- April ArmstrongLos Angeles$2.3M
- Jennifer HsiaoLos Angeles$746K
- Christopher HoLos Angeles$731K
- Howard SofenLos Angeles$345K
- Nada ElbulukLos Angeles$297K
- Derek JonesLos Angeles$272K
- Pearl GrimesLos Angeles$256K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.